Preclinical study demonstrates that wheat alkylresorcinols attenuate hepatic steatosis and insulin resistance in murine models, highlighting their promise as functional dietary ingredients.
Wheat alkylresorcinols (ARs) are phenolic lipids present in the bran part of whole grain wheat, which have been proven to improve obesity and atherosclerosis. However, the effects of ARs on hepatic steatosis and their possible mechanisms remain unclear. In the present study, ARs intervention significantly attenuated high-fat diet-induced hepatic steatosis, insulin resistance, and dyslipidemia. Meanwhile, RNA-seq and western-blot analysis in liver tissues among different treatment groups detected significant changes in pathways related to glycolipid metabolism, especially AMPK signaling pathway and transmission. Moreover, ARs treatment dose-dependently improved glucolipid metabolism through AMPK activation and GLUT4 translocation in PA-treated AML12 mouse hepatocytes model. However, the protective effect of ARs was reversed after pretreatment with AMPK inhibitor. Taken together, ARs can be used as a dietary functional ingredient to ameliorate glycolipid metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: